Figure 1.

Study design. This figure gives an overview of the study populations, different treatment periods (placebo run-in and active treatment period) and double-blind, placebo-controlled, randomized design of the study. Blood samples for biomarker assessments were collected on visits 2 through 5. An oral glucose tolerance test (OGTT) was performed at visit 2 (baseline) and visit 5 (end of the active treatment period)